The Bioenergetic Case for Strategic Fasting (Beyond Ray Peat's Cortisol Frame)

Few positions in the bioenergetic research community are as firmly settled - and as seldom re-examined - as the anti-fasting stance. Ray Peat (1936-2022) made his opposition to fasting explicit across decades of newsletters and interviews. The bioenergetic community he influenced absorbed that position, and it has persisted as something close to orthodoxy: fasting is a stress response, cortisol is the mechanism, and a research subject whose central problem is already metabolic suppression has nothing to gain and something real to lose by triggering that cortisol cascade. The reasoning is coherent and the mechanistic foundation is sound.

This post does not argue that Peat was wrong. It argues that Peat's anti-fasting position was correct in the specific context he was addressing - euthyroid or subclinical-hypothyroid research subjects without exogenous thyroid hormone supplementation - and that the context changes materially when T3 is being delivered exogenously. The cortisol argument that Peat made depends on a chain of mechanistic steps, and one of those steps - the suppression of endogenous T3 by cortisol - does not function the same way for research subjects whose T3 is arriving from an external source rather than being produced by their own thyroid-deiodinase axis. That single change in the input conditions rewrites the calculus on strategic fasting in a way that is worth examining carefully.

The bioenergetic research community is not monolithic on this question, and the position developed here represents a research-community theory rather than a clinical protocol or a settled consensus. The mechanistic reasoning is the subject; the audience is researchers already familiar with the Peat framework who are evaluating whether strategic fasting belongs in an adequately T3-supported bioenergetic protocol.

Research framing. This article reviews strategic fasting and T3 replacement from a research-context standpoint. All compounds discussed are sold strictly for laboratory research and not for human consumption. See our /faq#legality page for full terms.

Peat's Anti-Fasting Argument: Cortisol and the Stress Response

Peat's opposition to fasting was not vague or impressionistic - it was mechanistically specific, and it deserves to be represented accurately before it is critiqued. The argument ran as follows.

Fasting - any significant caloric restriction below the threshold needed to maintain blood glucose from dietary sources - triggers a predictable hormonal response. Blood glucose falls as liver glycogen depletes. The body responds by releasing glucagon (from the pancreas), adrenaline (from the adrenal medulla), and cortisol (from the adrenal cortex). The purpose of this hormonal cascade is to mobilize stored fuel: cortisol initiates protein catabolism, converting amino acids to glucose through gluconeogenesis; glucagon signals the liver to release stored glycogen and ramp up gluconeogenesis; adrenaline mobilizes fatty acids from adipose tissue.

In Peat's framework, cortisol is not a neutral mobilization tool - it is a primary metabolic suppressor. The research literature he drew on documents cortisol's effects on thyroid hormone metabolism: cortisol inhibits the type 1 deiodinase (DIO1) enzyme responsible for converting T4 to the active T3, and simultaneously promotes the shunting of T4 toward reverse T3 (rT3) production rather than active T3. The net effect is a reduction in circulating T3 - precisely the hormone that Peat's framework identifies as the master metabolic regulator. A research subject who begins a fast with a marginally adequate metabolic rate may exit it with a measurably lower T3 and a higher rT3, a trajectory that is the opposite of metabolic optimization.

Cortisol's antagonism to T3 does not end at the deiodinase enzyme. Glucocorticoids also reduce thyroid hormone receptor sensitivity at the tissue level, blunting the cellular response to whatever T3 remains available. In the chronic-illness population - which Peat understood as a population characterized by already-suppressed metabolic rate, already-elevated cortisol baseline, and already-compromised deiodinase function - this additional cortisol load from fasting is not a trivial insult. It is a setback that can take weeks to recover from.

Peat also challenged fasting's purported benefits on mechanistic grounds. The autophagy and mitochondrial biogenesis attributed to fasting, he argued, are byproducts of the same stress-hormone elevation - hormetic responses to a cortisol and adrenaline cascade - rather than direct metabolic improvements. His position was that a research subject maintaining adequate metabolic rate through T3 support and the anti-stress dietary framework could achieve the same cellular maintenance functions without the cortisol cost. This is a coherent mechanistic argument. It is also the argument that changes when T3 replacement is in place.

The pillar overview of the bioenergetic framework, including the fasting debate context, is covered in full in the Ray Peat protocol 2026 research guide.

The Missing Variable: T3 Replacement

Peat's cortisol-fasting-T3 chain is a causal sequence with specific links. Link one: fasting elevates cortisol. Link two: cortisol suppresses T3 via DIO1 inhibition and rT3 shunting. Link three: reduced T3 means reduced metabolic rate. Link four: reduced metabolic rate is the opposite of what the research subject is trying to achieve.

Links one, three, and four are broadly applicable. Link two - the DIO1-mediated cortisol suppression of T3 - is where the context-dependency enters. That link describes what happens when cortisol acts on the body's own T3 production machinery. It assumes that T3 is endogenously generated, that cortisol's effects on deiodinase and rT3 production therefore determine T3 availability, and that reducing the efficiency of that enzymatic machinery reduces active T3 in proportion.

For research subjects on exogenous T3 replacement, this link functions differently. Cortisol can inhibit DIO1 as effectively as it ever did, and it can drive rT3 production from any residual T4, but neither of those effects changes the T3 being delivered directly from the supplement. The active T3 arriving through the sustained-release formulation is not gated by DIO1 activity. Cortisol cannot suppress what the thyroid-deiodinase axis is not producing. The T3 stream from exogenous supplementation continues regardless of cortisol's effects on endogenous conversion, and the research subject's serum T3 - while not completely immune to cortisol's influence at the receptor level - is no longer determined by the enzymatic bottleneck that Peat's argument targeted.

This does not mean that cortisol during fasting is irrelevant for the T3-supplemented research subject. Cortisol still reduces thyroid hormone receptor sensitivity, still promotes protein catabolism, and still represents a stress-axis burden that the bioenergetic framework treats as generally undesirable. The argument is not that cortisol becomes harmless under T3 replacement - it is that the specific and most important mechanism through which Peat argued fasting was counterproductive (the suppression of T3 via deiodinase inhibition and rT3 shunting) is substantially neutralized when T3 is arriving exogenously rather than being enzymatically converted.

The pharmacokinetic profile of SR-T3 is particularly relevant to this revised calculation. Sustained-release T3 delivered in a hydroxypropyl methylcellulose (HPMC) matrix produces a flat serum curve over a 4-8 hour window, avoiding the sharp peak-and-trough pattern of immediate-release T3. During a fasting window - when cortisol may be modestly elevated and when the research subject is not taking in dietary substrates - it is this flat, sustained pharmacokinetic profile that determines whether receptor occupancy is maintained. A sustained-release formulation that keeps serum T3 stable through the fasting period is mechanistically distinct from an immediate-release dose taken before the fast: the flat curve maintains thyroid hormone receptor occupancy continuously, meaning the tissue-level T3 signal does not collapse into the cortisol-driven trough that Peat's argument assumed. The sustained-release T3 complete guide covers the pharmacokinetic reasoning in detail. For research reference, the Wilson's SR-T3 Combo is the sustained-release formulation that most directly instantiates this pharmacokinetic profile.

Mitochondrial Biogenesis: What Fasting Unlocks

The case for strategic fasting in the bioenergetic framework is not purely defensive (defending against Peat's objection) - it is also affirmative. Fasting activates a specific set of metabolic signaling pathways that are directly relevant to the cellular dysfunction profile the bioenergetic protocol is trying to address.

The central pathway is AMPK activation. When cellular energy status falls - as it does during fasting, when glucose and ATP availability decrease - AMP-activated protein kinase (AMPK) is phosphorylated and activated. AMPK functions as a cellular energy sensor: once active, it drives a coordinated program of metabolic adaptation that includes upregulation of fatty acid oxidation, suppression of anabolic energy expenditure, and activation of PGC-1alpha (peroxisome proliferator-activated receptor gamma coactivator 1-alpha). PGC-1alpha is the master transcriptional regulator of mitochondrial biogenesis - it drives the expression of genes encoding mitochondrial proteins and promotes the replication of mitochondrial DNA. The result of sustained AMPK activation, expressed over the course of multiple fasting cycles, is an increase in mitochondrial number per cell and mitochondrial density per unit of tissue.

SIRT1 (sirtuin 1) activation runs in parallel. SIRT1 is an NAD+-dependent deacetylase that is upregulated when cellular NAD+ rises during fasting - a consequence of the same shift in cellular energy substrate away from glycolysis and toward oxidative phosphorylation. SIRT1 deacetylates and activates PGC-1alpha, compounding the mitochondrial biogenesis signal from AMPK. The two pathways are not redundant - they are additive, and both are activated by caloric restriction and fasting in the experimental literature [PMID: 16607139].

For a research subject with a chronic-illness presentation centered on mitochondrial dysfunction - reduced oxidative phosphorylation efficiency, impaired electron transport complex activity, insufficient ATP synthesis per unit of metabolic substrate - the AMPK/SIRT1/PGC-1alpha axis addresses the structural problem directly. More mitochondria per cell means more capacity for oxidative phosphorylation, more electrons moved through the electron transport chain per unit time, more ATP available for metabolically demanding tissues. This is not a peripheral benefit - it targets the same substrate-level problem that T3 supplementation is targeting through nuclear receptor upregulation of mitochondrial enzyme expression. The two approaches - exogenous T3 driving mitochondrial enzyme transcription, and strategic fasting driving AMPK/SIRT1 mitochondrial biogenesis - are mechanistically complementary. They work through different signals on overlapping downstream targets.

The T2 Connection

The T3→T2 conversion problem is a recognized gap in the Peat framework that the bioenergetic research community has only recently begun to address systematically. 3,5-diiodothyronine (3,5-T2) - the downstream metabolite of T3 deiodination via DIO1 - binds directly to subunit Va of cytochrome c oxidase (Complex IV of the mitochondrial electron transport chain) and acutely drives mitochondrial respiration independently of nuclear thyroid hormone receptor signaling. This is a distinct mitochondrial activation mechanism that T3 alone does not accomplish. Research subjects whose DIO1 enzyme is impaired by selenium deficiency, elevated cortisol, or inflammatory cytokines may be generating adequate T3 for nuclear receptor signaling while leaving the cytochrome c oxidase-direct pathway substantially unsupported - the T3 protocol plateau that the community describes is mechanistically attributable to this T3→T2 conversion bottleneck.

The fasting-T2 intersection follows directly from the biogenesis argument in the previous section. Fasting drives mitochondrial biogenesis: more mitochondria per cell, more cytochrome c oxidase complexes per cell. 3,5-T2 activates those cytochrome c oxidase complexes directly and acutely. The combination - more enzyme and more direct activation of that enzyme - is conceptually coherent as a pairing. A research subject combining strategic fasting (for biogenesis) with T2 supplementation (for direct mitochondrial activation) is addressing the same mitochondrial pathway from two angles: structural capacity through biogenesis, and acute functional activation through T2's cytochrome c oxidase binding.

The DIO1 dysfunction that blocks T3→T2 conversion is often the same inflammatory and cortisol-driven impairment that blocks T4→T3 conversion - the deiodinase dysfunction problem runs through both conversion steps. The full mechanistic detail, including the deiodinase enzyme dysfunction overlap and the plateau pattern, is covered in the T3 to T2 conversion problem and deiodinase dysfunction guide. For research reference, the Wilson's T3+T2 Combo addresses both the T3 nuclear receptor pathway and the T2 cytochrome c oxidase pathway in a single sustained-release formulation, making it the most complete bioenergetic thyroid research product for the combined-approach context.

Autophagy: Where the Post-Peat Literature Extends the Framework

Mitochondrial biogenesis is only half the cellular maintenance picture that fasting activates. The other half is autophagy - the lysosomal degradation system through which cells clear damaged organelles, misfolded proteins, and other cellular debris that accumulates over time and under metabolic stress.

Autophagy induction by fasting is one of the most robustly documented mechanistic effects in the relevant literature, work recognized by the 2016 Nobel Prize in Physiology or Medicine [PMID: 28686685]. The pathway is AMPK and mTOR-dependent: AMPK activation during fasting suppresses mTORC1 (the mammalian target of rapamycin complex 1, which normally inhibits autophagy when nutrients are abundant), and the release of mTORC1 suppression allows the ULK1 autophagy-initiation kinase to proceed. The result is a coordinated induction of autophagic flux - the formation of autophagosomes that engulf cellular debris and fuse with lysosomes for degradation and component recycling.

The cellular debris that autophagy targets is directly relevant to the chronic-illness and bioenergetic-framework context. Damaged mitochondria - organelles whose electron transport chains have been impaired by lipid peroxidation, reactive oxygen species, or inflammatory damage - are specifically cleared through mitophagy, the mitochondria-targeted branch of the autophagy program. Dysfunctional mitochondria that are consuming cellular resources without producing adequate ATP are not just inefficient; they are sources of excess reactive oxygen species that damage surrounding mitochondria and cellular structures. Clearing them through mitophagy and replacing them with newly biogenerated mitochondria is the cellular renewal cycle that sustains long-term mitochondrial health.

The lipid peroxidation connection is worth noting explicitly for the Peat-framework context. Peat's anti-PUFA argument is built on the well-documented tendency of polyunsaturated fatty acids, once incorporated into membrane phospholipids, to undergo lipid peroxidation and generate reactive aldehyde products (4-HNE, malondialdehyde) that damage mitochondrial enzymes. Autophagy and mitophagy clear the downstream products of that peroxidative damage - damaged proteins, oxidized lipid aggregates, peroxidatively compromised organelles. Research subjects who have accumulated years of PUFA-driven mitochondrial damage have, in principle, a substantial autophagic clearance task. Strategic fasting is the strongest available signal for initiating that clearance at scale.

Strategic Fasting Protocols in the Bioenergetic Community

The bioenergetic research community discusses several fasting patterns in the context of T3 replacement protocols. The specific schedules that come up most frequently are summarized below.

The community discussion around these patterns reflects Peat's cortisol concern as a calibrating variable - shorter fasting windows (TRF at 14:10 or 16:8) generate a more modest cortisol response than multi-day fasts, and the community generally treats this as the relevant entry point for research subjects who are newly pairing strategic fasting with T3 protocols. The longer patterns (alternate-day and weekly 36-48h) generate stronger biogenesis and autophagy signals but also a stronger cortisol response, and are typically discussed in the context of research subjects with stable, well-established T3 dosing.

What This Looks Like in Practice

In the bioenergetic research community's discussion of strategic fasting paired with T3 replacement, several practical themes appear consistently.

Time-restricted feeding is the most frequently discussed entry point, precisely because it minimizes the cortisol response that Peat's anti-fasting argument was most concerned about. A 16:8 TRF pattern - eating within an 8-hour window, fasting for the remaining 16 hours of which the majority are overnight - generates a modest and brief cortisol elevation rather than the sustained cortisol exposure of a multi-day fast. The overnight component means most of the fasting window occurs during normal sleep, when the HPA axis is already operating in a lower-output state. The practical cortisol burden of 16:8 TRF is therefore substantially lower than the multi-day fasting protocols that generated the most concern in traditional fasting research.

Research subjects on SR-T3 maintenance dosing in this context typically maintain their normal SR-T3 dosing schedule through the fasting window. Sustained-release T3 formulations in HPMC matrix do not depend on food intake for absorption, making fasted-state dosing pharmacokinetically equivalent to fed-state dosing. This is mechanistically important: it means the stable serum T3 curve that SR-T3 produces is not disrupted by the fasting window, and the receptor-occupancy rationale for why T3 replacement changes the cortisol calculus is maintained throughout the fast.

The bioenergetic research community discussion also consistently identifies several categories of research subjects for whom strategic fasting is generally deferred until other protocol elements are stabilized. Research subjects with active reverse T3 dominance - where the rT3:fT3 ratio is clearly elevated - typically focus on rT3 clearance before adding fasting to the protocol, since the deiodinase environment that produces elevated rT3 is already expressing the cortisol-driven T3 suppression that Peat's argument identified. Research subjects with severe HPA dysregulation, where the cortisol diurnal pattern is significantly blunted or inverted, similarly benefit from HPA stabilization before adding the cortisol-stimulating element of fasting. And research subjects who are still in active T3 dose adjustment - who have not yet established a stable, well-tolerated SR-T3 dose - are typically advised in community discussion to defer fasting until dosing stability is established. The rationale in each case is the same: the protective mechanism that changes the fasting calculus (stable exogenous T3) needs to be operational before fasting's cortisol response is introduced.

Research context governs all of this discussion. The community frameworks described here are not clinical protocols and not prescriptive guidance - they are the practical reasoning patterns that bioenergetic-framework researchers have developed through experimentation and forum discussion. Time-restricted feeding research using [PMID: 30404766 methodology] provides the experimental-design context for the metabolic-flexibility claims associated with TRF.

What Research Has and Hasn't Established

Established:

Fasting drives autophagy - this is among the most robustly documented effects in contemporary cell biology. The mechanism (AMPK/mTOR/ULK1) is characterized at molecular resolution, and autophagic flux induction by caloric restriction has been demonstrated across cell types, model organisms, and - to a sufficient degree - in human peripheral blood mononuclear cells. Fasting drives mitochondrial biogenesis via the AMPK/SIRT1/PGC-1alpha axis - documented in the caloric restriction literature with both cell-biology resolution and some animal-model longitudinal data [PMID: 16607139]. Fasting elevates cortisol in euthyroid baseline subjects - documented with direct measurement in the fasting-cortisol literature [PMID: 3791672], and the cortisol-DIO1 suppression link is characterized in the thyroid-cortisol axis research [PMID: 26869017].

Hypothesis:

T3 replacement neutralizes the cortisol-antagonism concern Peat raised. This is mechanistically coherent - the chain of reasoning from exogenous T3 delivery to reduced dependence on DIO1-mediated T3 production follows from established pharmacokinetics and endocrinology - but it has not been validated in a randomized controlled trial of chronic-illness research subjects on SR-T3 maintenance dosing subjected to standardized fasting protocols with T3 and cortisol measurement. The hypothesis sits in the category of community-derived mechanistic reasoning: individually supported components, integrated application lacking prospective controlled validation.

Not endorsed by mainstream endocrinology or by the orthodox Ray Peat community:

Strategic fasting paired with T3 replacement remains a research-community position, not a consensus protocol. Mainstream endocrinology does not endorse exogenous T3 supplementation for most thyroid presentations, let alone for pairing with fasting protocols. The orthodox Peat community continues to hold Peat's anti-fasting position as foundational and has not broadly adopted the T3-replacement-changes-the-calculus framing. This post represents a specific minority position within the bioenergetic research community - one grounded in mechanism but not backed by the clinical-trial evidence that would move it toward mainstream acceptance.

Frequently Asked Questions

Did Ray Peat support fasting?

No - Peat's opposition to fasting was consistent and explicit across his newsletters and interviews. He argued that fasting elevated cortisol and adrenaline, that those stress hormones suppressed T3 via deiodinase inhibition and reverse T3 shunting, and that the net metabolic effect was suppression rather than enhancement. Peat also challenged the mechanism behind fasting's purported benefits, arguing that autophagy and mitochondrial biogenesis attributed to fasting were byproducts of stress-hormone elevation rather than direct metabolic improvements. His position was held consistently from his early writing through the interviews he gave in the final years before his death in 2022.

Why did Ray Peat oppose fasting?

Peat's opposition was grounded in the cortisol-T3 axis. When fasting depletes liver glycogen and drops blood glucose, the HPA axis releases cortisol, which inhibits the type 1 deiodinase enzyme responsible for T4-to-T3 conversion and promotes T4 shunting toward inactive reverse T3 instead. For Peat, who built his framework around T3 as the master metabolic regulator, anything that reduced T3 availability was metabolically counter-productive. The chronic-illness research subject - already characterized by suppressed metabolic rate, marginal T3 availability, and a cortisol axis under chronic load - had, in Peat's view, nothing to gain from adding more cortisol load. He regarded fasting as a misapplication of hormetic reasoning to a population that was not starting from a position of metabolic robustness.

Does T3 replacement change the fasting calculus?

This is the central question the bioenergetic research community is actively working through, and the position developed here is that yes, it changes the calculus materially. Peat's cortisol argument assumes that cortisol's effects on deiodinase and reverse T3 production determine T3 availability - which is true for research subjects relying on endogenous T3 production. For research subjects on exogenous sustained-release T3, the active T3 supply is not gated by DIO1 activity or rT3 shunting. The specific mechanistic link that made cortisol most damaging in Peat's framework is therefore partially bypassed. This does not make cortisol harmless - it retains its receptor-sensitivity effects - but it changes the cost-benefit analysis for strategic fasting substantially.

Is intermittent fasting safe on slow-release T3?

Safety is a clinical question that falls outside the scope of research-community discussion, and the answer to this question depends on individual health status in ways that cannot be generalized. What the bioenergetic research community discusses is the mechanistic compatibility of SR-T3's pharmacokinetic profile with fasting windows - and on that question, the flat serum T3 curve that SR-T3 produces is mechanistically well-suited to maintaining receptor occupancy through a fasting period. SR-T3 formulations in HPMC matrix do not require food for absorption. Research subjects considering this pairing should discuss it with a qualified healthcare provider.

What about cortisol on fasting?

Cortisol elevation during fasting is well-documented in the research literature and is not disputed in the bioenergetic community. The position here is not that cortisol does not rise during fasting - it does - but that the specific and most consequential pathway through which Peat argued that cortisol was damaging (suppression of endogenous T3 production via DIO1 inhibition) is substantially bypassed when T3 is being delivered exogenously. Cortisol retains its receptor-desensitizing effects and its protein-catabolic effects under T3 replacement. The argument is a partial neutralization of Peat's cortisol objection, not a complete dismissal of cortisol's fasting-state activity.

How does fasting affect T3 to T2 conversion?

The T3→T2 conversion step, like T4→T3 conversion, depends on DIO1 deiodinase activity. Cortisol elevation during fasting - which suppresses DIO1 - would be expected to reduce T3→T2 conversion in addition to reducing T4→T3 conversion. For research subjects relying on endogenous T3→T2 conversion to generate the cytochrome c oxidase-active 3,5-T2, fasting may reduce T2 availability alongside T3. This is one argument for combining T2 supplementation directly with T3 in a fasting-compatible protocol - bypassing the T3→T2 conversion bottleneck the same way that T3 supplementation bypasses the T4→T3 bottleneck. The T3+T2 combination approach is the most complete bioenergetic response to this issue.

What kind of fasting do bioenergetic researchers discuss?

The community discussion focuses primarily on time-restricted feeding (TRF) - specifically 14:10 and 16:8 patterns - as the entry-point format most compatible with T3 replacement protocols. TRF generates a modest and brief cortisol response compared to multi-day fasts, with the overnight component of the fasting window occurring during normal sleep when HPA-axis output is already attenuated. Longer patterns, including alternate-day modified fasting and weekly 36-48h fasts, are discussed in the community in the context of research subjects with stable T3 dosing who are seeking a stronger autophagy and mitochondrial biogenesis signal. These longer patterns are consistently framed in community discussion as appropriate only after stable T3 status is established.

Should I fast if I have reverse T3 dominance?

This is a clinical question that cannot be answered in a research context. What bioenergetic research community discussions consistently note is that the protective mechanism that changes the fasting calculus - stable exogenous T3 supply maintaining serum T3 through the fasting cortisol response - needs to be in place before fasting is introduced. Research subjects with active rT3 dominance (elevated rT3:fT3 ratio) are typically still in the process of establishing that stable T3 status, and community discussion generally treats rT3 clearance and T3 stabilization as prior steps to strategic fasting. Adding fasting's cortisol load while the deiodinase environment is actively producing excess rT3 would, in the community's reasoning, tend to compound the problem rather than address it.

Closing Note

This post develops research-community theory anchored on real mechanism: the cortisol-DIO1-T3 pathway that Peat documented is well-supported biochemistry, and the pharmacokinetic reasoning for why exogenous sustained-release T3 changes the way that pathway operates is internally coherent. The hypothesis that T3 replacement neutralizes Peat's primary fasting objection awaits the controlled-trial validation that would move it from community theory to established protocol. For researchers investigating this intersection from the T2 angle specifically - examining how 3,5-T2's cytochrome c oxidase mechanism interacts with fasting-driven mitochondrial biogenesis - the companion analysis is in Ray Peat's anti-fasting position reconsidered in the context of T2. The Wilson's T3+T2 Combo is the reference compound product for the combined T3+T2 approach, and the full catalog covers the complete bioenergetic-framework research stack.